Recombinant Human LIGHT/TNFSF14 protein (His Tag)

ED50

0.1-0.4 ng/mL

Species

Human

Purity

>95 %, SDS-PAGE

GeneID

8740

Accession

O43557

Cat No : Eg32095

Print datasheet

Synonyms

CD258, HVEML, HVEM-L, LIGHT, LTg, TNFSF14, TR2



Technical Specifications

Purity >95 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Immobilized Human HVEM (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Human LIGHT (His tag) with a linear range of 0.1-0.4 ng/mL.
Source HEK293-derived Human LIGHT protein Asp74-Val240 (Accession# O43557) with a His tag at the N-terminus.
Predicted Molecular Mass 19 kDa
SDS-PAGE 20-22 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Tumor necrosis factor superfamily member 14 (TNFSF14), LIGHT, is a component of the cytokine network that regulates innate and adaptive immune responses, which promote homeostasis of lymphoid organs, liver, and bone. TNFSF14 is an immunomodulatory cytokine and a member of the TNF superfamily. It is expressed by lymphocytes, monocytes, and granulocytes, and is primarily known for its critical role in immune functions. TNFSF14 leads to T cell activation through interaction with HVEM by enhancing T cell proliferation and induces cytokine secretion through binding to lymphotoxin β receptor (LTβR) on mast cells. TNFSF14 has also been implicated in various pathogenic conditions related to inflammatory responses such as tumors, type 2 diabetes, and atherosclerosis.

References:

1.Giacomina Brunetti. et al. (2020). J Bone Miner Res. 35(4):671-680 2.Marcos W Steinberg. et al. (2011). Immunol Rev. 244(1):169-187. 3.K Tamada. et al. (2000). J Immunol. 164(8):4105-4110. 4.Peter Stopfer. et al. (2004). J Immunol. 172(12):7459-7465. 5.W H Lee. et al. (2001). Arterioscler Thromb Vasc Biol. 21(12):2004-2010.